Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study

Summary

The goal of the clinical trial is to assess the presence of circulating tumor cells (CTCs) in the blood and/or cerebrospinal fluid (CSF) of patients with aggressive recurrent meningiomas.

Eligibility

Inclusion Criteria:

* Over 18 years of age
* Operated on for a grade 2 or 3 meningioma at Montpellier University Hospital between 2015 and 2024
* Tumour expressing SSTR2A on the initial surgical specimen
* Clinical and/or radiological recurrence as determined by MRI imaging (progression of a residual lesion OR appearance of a new lesion consistent with a meningioma at the surgical site or elsewhere)

Exclusion Criteria:

* Other active ongoing cancer
* Contraindications to lumbar puncture:
* Intracranial hypertension with meningioma exerting a mass effect and obstruction of the cerebrospinal fluid (CSF) pathway/risk of trans-tentorial or amygdalar herniation
* Blood clotting disorder with risk of haematoma at the puncture site (anticoagulant treatment at therapeutic dose or antiplatelet therapy, thrombocytopenia or thrombopathy)
* Infection at the puncture site
* Pregnant or breastfeeding women (Article L.1121-5 of the French Public Health Code)
* Persons deprived of their liberty by judicial or administrative decision (Article L.1121-6 of the French Public Health Code)
* Persons who are subject to legal protection measures or who are unable to express their consent (guardianship, curatorship, judicial protection; Article L.1121-8 of the French Public Health Code)
* Not affiliated with a social security scheme or beneficiary of such a scheme (Article L.1121-8-1 of the French Public Health Code)
* Persons participating in another study that includes an ongoing exclusion period (Article L.1121-12 of the French Public Health Code)
* Failure to obtain written informed consent

Conditions2

Browse More Trials